Merck said that in a final analysis of a clinical trial, its antiviral pill reduced the risk of hospitalization and death among high-risk Covid patients by 30%, down from an earlier estimate of 50%.https://t.co/CyqB8kkQFD

— The New York Times (@nytimes) November 26, 2021